- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02520791
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Study Overview
Status
Conditions
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Stage IB Mycosis Fungoides AJCC v7
- Stage II Mycosis Fungoides AJCC v7
- Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage III Mycosis Fungoides AJCC v7
- Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage IV Mycosis Fungoides AJCC v7
- Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
- Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), follicular lymphoma, mycosis fungoides (MF) and cutaneous T-cell lymphomas (CTCL).
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of MEDI-570. II. To evaluate the overall response rate (ORR) and progression free survival (PFS) of MEDI-570 at all dose levels and in a 10-patient expansion cohort at the maximum tolerated dose (MTD).
III. To determine short and long term effects of MEDI-570 at all dose levels on the immune system and on T-cell lymphocyte subsets.
IV. To determine the relationship between ICOS expression on tumor cells and response to MEDI-570.
EXPLORATORY OBJECTIVE:
I. To evaluate biomarkers of response and resistance to MEDI-570 in the study population.
OUTLINE: This is a dose-escalation study.
Patients receive anti-ICOS monoclonal antibody MEDI-570 intravenously (IV) over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6 weeks for 12 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA-Vancouver Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, United States, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
New Haven, Connecticut, United States, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- University of Kansas Clinical Research Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky/Markey Cancer Center
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Siteman Cancer Center at West County Hospital
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63129
- Siteman Cancer Center-South County
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center-Einstein Campus
-
Bronx, New York, United States, 10467
- Montefiore Medical Center - Moses Campus
-
Bronx, New York, United States, 10461
- Montefiore Medical Center-Weiler Hospital
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Pathologic diagnosis of one of the following:
For dose escalation:
- Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy; anaplastic large cell lymphoma (ALCL) and natural killer T-cell lymphoma nasal type (NKTCL) are excluded
- Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis are excluded
Follicular lymphoma grade 1, 2 or 3A that meets the following criteria:
- Relapsed or refractory to at least 2 lines of therapy AND
- Relapsed or refractory post autologous cell transplantation (HCT)
For dose expansion/dose confirmation phase:
- Patients with confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular type or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy
- At least 14 days from the last therapy dose or 5 half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade 2 or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of 2 weeks and resolution of all acute toxicity will be required
- Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC] criteria)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 6 months
- Leukocytes >= 3,000/mcL
Hemoglobin >= 80 d/L (or >= 8 g/dL)
- Patients must not have received a transfusion, with packed red blood cells, within 2 weeks prior to sample being collected
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets (PLT) >= 50,000/mcL
- Absolute CD4 count > 100 cells/uL
- Total bilirubin < 1.5 upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
- Creatinine < 1.5 mg/dl (= 132 umol/L) or
- Creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
In patients with bone marrow involvement the minimum requirement is as follows:
- Leukocytes >= 2000/mcL
- ANC >= 1000/mcL
- PLT >= 50 000/mcL
- Availability of tissue for correlative studies; patients must have at least 6-8 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available; if not enough archived tissue is available, a fresh tumor biopsy prior to study initiation is mandatory; for patients who have undergone a fresh baseline biopsy at baseline, the archived tissue is not mandatory
- The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who are receiving any other investigational agents
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
- Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
- Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study's principal investigator
- History of human immunodeficiency virus (HIV) infection; the human immunodeficiency virus (HIV) depletes CD4 T-cells and could also have a role in T-cell anergy; since MEDI-570 preferentially affects CD4 T-cell numbers and function, and the resultant immunosuppression by this agent can be prolonged, exposing HIV patients to MEDI-570 will place them in an unnecessary risk of developing infections due to an underlying acquired cellular immunity defect
- History of primary immunodeficiency
- Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
- All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB
- Patients who have undergone allogeneic stem cell transplantation
- Patients who have undergone autologous stem cell transplantation within 3 months from study entry
- Major surgery within 30 days prior or during the study period
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study due to the potential toxicity in pre-clinical reproductive studies; in addition, there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MEDI-570; breastfeeding should be discontinued if the mother is treated with MEDI-570
Patients with active, known, or suspected autoimmune disease, except in these conditions:
- Participants with well-controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible
Participants with the following disease conditions are also eligible:
- Vitiligo,
- Type 1 diabetes mellitus
- Residual hypothyroidism due to autoimmune condition only requiring hormone replacement
- Euthyroid participants with a history of Grave's disease (participants suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study drug)
- For patients with ITP (idiopathic thrombocytopenic purpura) or AIHA (autoimmune hemolytic anemia), a case by case discussion with study principal investigator (PI) may be considered
- Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years can be also eligible
- Patients with a weight of < 39 kg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (MEDI-570)
Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1.
Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of toxicity and safety of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Time Frame: Up to 12 weeks after completion of study treatment
|
Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest.
Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.
|
Up to 12 weeks after completion of study treatment
|
Maximum tolerated dose (MTD) of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Time Frame: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0.
|
Up to 21 days
|
Recommended phase 2 dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Time Frame: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0.
|
Up to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK), such as plasma concentration and PK parameters, of monoclonal antibody therapy
Time Frame: Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted.
|
Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
Overall response rate
Time Frame: Up to 36 weeks
|
Assessed per the Revised Response Criteria for Malignant Lymphoma of the Lugano Classification.
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests.
A p-value of 0.05 or less will be considered statistically significant.
|
Up to 36 weeks
|
Progression-free survival
Time Frame: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests.
A p-value of 0.05 or less will be considered statistically significant.
|
Up to 12 weeks after completion of study treatment
|
Immunogenicity
Time Frame: Up to 36 weeks
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests.
A p-value of 0.05 or less will be considered statistically significant.
|
Up to 36 weeks
|
Overall survival (OS)
Time Frame: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests.
A p-value of 0.05 or less will be considered statistically significant.
|
Up to 12 weeks after completion of study treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers of response and resistance to anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Time Frame: Up to 36 weeks
|
Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate.
Potential predictors include clinical predictors and molecular correlates.
Descriptive statistics and plotting of data will also be used to better understand potential relationships.
|
Up to 36 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julio C Chavez, University Health Network Princess Margaret Cancer Center LAO
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Bacterial Infections and Mycoses
- Lymphadenopathy
- Lymphoma
- Lymphoma, Follicular
- Recurrence
- Lymphoma, Non-Hodgkin
- Mycoses
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides
- Immunoblastic Lymphadenopathy
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Antibodies, Monoclonal
Other Study ID Numbers
- NCI-2015-01271 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- UM1CA186644 (U.S. NIH Grant/Contract)
- PJC-021
- 9930 (Other Identifier: CTEP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Grade 1 Follicular Lymphoma
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States, Canada, Singapore
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedFollicular Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States